A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.
Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:
Baxter's has 'high' hopes for its coming Baxalta spinout, which will get a full visual work-up before the company goes live mid-2015.
Baxter (NYSE:BAX) crept a little closer to spinning out its biopharmaceuticals division into an independent entity by giving the company a name: Baxalta.
Allergan confirmed late last week that it would call the shareholder meeting demanded by unsolicited buyers Valeant Pharmaceuticals and activist investor William Ackman.
Valeant Pharmaceuticals files a lawsuit aiming to force Allergan to hold a special shareholder meeting after hand-delivering 1,500 pages of documents showing shareholder support.
Valeant Pharmaceuticals and Pershing Square Capital Management reportedly plan to ask Allergan for a shareholder vote on their hostile takeover attempt, after a federal judge rules that Allergan's insider trading lawsuit won't delay the meeting.
Allergan reportedly solicits Salix Pharmaceuticals in a bid to stymie the $53 billion hostile takeover move by Valeant Pharmaceuticals and Pershing Square Capital Management.
The U.S. Securities & Exchange Commission is launching an insider trading probe into the hostile takeover bid for Allergan by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital, even as Allergan inks a $588 million deal for Taris Biomedical's Liris bladder drug and Ackman dangles the prospect of an IPO for Pershing Square.